Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection

MT Newswires Live

2024/09/19

Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.

The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.

The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.

Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2468410519"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2468410519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2468410519?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 12:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468410519","market":"us","top_or_hot":-1,"title":"Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection","media":"MT Newswires Live","content":"<html><body><p> Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.</p><p>The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.</p><p>The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.</p><p>Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-09-19 12:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.</p><p>The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.</p><p>The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.</p><p>Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"質押式回購","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468410519","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468410519","pubTimestamp":1726721145,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Yifan Pharmaceutical  unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.Price : 10.31, Change: +0.17, Percent Change: +1.68%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0077":"质押式回购","BK0191":"维生素","BK0197":"中小创蓝筹","002019":"亿帆医药","BK0239":"医药制造","BK0185":"二线龙头","BK0070":"员工持股"},"translate_title":"亿帆药业法莫替丁注射液上市获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002019":0.9},"content_text":"Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.Price (RMB): Â¥10.31, Change: Â¥+0.17, Percent Change: +1.68%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}